Section Edited by Claudia Palena, PhD and Eric Tartour, MD, PhD
Tumor antigens, innate and adaptive anti-tumor immune mechanisms, immune regulation, immune response, cancer and inflammation, preclinical models, chemotherapy and radiotherapy interactions/combinations of chemotherapy and radiotherapy, and other combination treatments with the anti-tumor immune response.
circ-0000512 inhibits PD-L1 ubiquitination through sponging miR-622/CMTM6 axis to promote triple-negative breast cancer and immune escapeLi-Feng Dong, Fang-Fang Chen, Yang-Fan Fan, Kun Zhang, Hui-Hui Chen
22 June 2023
New hormone receptor-positive breast cancer mouse cell line mimicking the immune microenvironment of anti-PD-1 resistant mammary carcinomaMaria Perez-Lanzon, Vincent Carbonnier, Pierre Cordier, Fatima Domenica Elisa De Palma, Adriana Petrazzuolo, Christophe Klein, Floriane Arbaretaz, Khady Mangane, Gautier Stoll, Isabelle Martins, Helene Fohrer Ting, Juliette Paillet, Sophie Mouillet-Richard, Delphine Le Corre, Wenjjin XiaoSee the full list of authors
21 June 2023
Tryptophan depletion sensitizes the AHR pathway by increasing AHR expression and GCN2/LAT1-mediated kynurenine uptake, and potentiates induction of regulatory T lymphocytesMarie Solvay, Pauline Holfelder, Simon Klaessens, Luc Pilotte, Vincent Stroobant, Juliette Lamy, Stefan Naulaerts, Quentin Spillier, Raphaël Frédérick, Etienne De Plaen, Christine Sers, Christiane A Opitz, Benoit J Van den Eynde, Jingjing Zhu
21 June 2023
Discovery of a novel dual-targeting D-peptide to block CD24/Siglec-10 and PD-1/PD-L1 interaction and synergize with radiotherapy for cancer immunotherapyWenhui Shen, Peishang Shi, Qingyu Dong, Xiuman Zhou, Chunxia Chen, Xinghua Sui, Wentong Tian, Xueqin Zhu, Xiaoxi Wang, Shengzhe Jin, Yahong Wu, Guanyu Chen, Lu Qiu, Wenjie Zhai, Yanfeng Gao
21 June 2023
A highly selective humanized DDR1 mAb reverses immune exclusion by disrupting collagen fiber alignment in breast cancerJunquan Liu, Huai-Chin Chiang, Wei Xiong, Victor Laurent, Samuel C Griffiths, Jasmin Dülfer, Hui Deng, Xiujie Sun, Y Whitney Yin, Wenliang Li, Laurent P Audoly, Zhiqiang An, Thomas Schürpf, Rong Li, Ningyan Zhang
16 June 2023
2,5-dimethylcelecoxib alleviated NK and T-cell exhaustion in hepatocellular carcinoma via the gastrointestinal microbiota-AMPK-mTOR axisBanglun Pan, Zhanfei Chen, Xiaoxia Zhang, Zengbin Wang, Yuxin Yao, Xiaoxuan Wu, Jiacheng Qiu, Hua Lin, Liumin Yu, Haijian Tu, Nanhong Tang
14 June 2023
Robust IL-2-dependent antitumor immunotherapy requires targeting the high-affinity IL-2R on tumor-specific CD8 T cellsKathryn M LaPorte, Rosmely Hernandez, Alicia Santos Savio, Thomas R Malek
2 June 2023
Anti-HVEM mAb therapy improves antitumoral immunity both in vitro and in vivo, in a novel transgenic mouse model expressing human HVEM and BTLA molecules challenged with HVEM expressing tumorsClémence Demerlé, Laurent Gorvel, Marielle Mello, Sonia Pastor, Clara Degos, Ana Zarubica, Fabien Angelis, Frédéric Fiore, Jacques A Nunes, Bernard Malissen, Laurent Greillier, Geoffrey Guittard, Hervé Luche, Fabrice Barlesi, Daniel Olive
25 May 2023
Dual TLR9 and PD-L1 targeting unleashes dendritic cells to induce durable antitumor immunityLaura Fernandez-Rodriguez, Chiara Cianciaruso, Ruben Bill, Marcel P Trefny, Richard Klar, Nicole Kirchhammer, Mélanie Buchi, Julia Festag, Sven Michel, Rainer H Kohler, Elham Jones, Andre Maaske, Johannes vom Berg, Sebastian Kobold, Abhishek S KashyapSee the full list of authors
19 May 2023
Dual receptor T cells mediate effective antitumor immune responses via increased recognition of tumor antigensHyun J Jang, Christine Caron, Calvin K Lee, Lu Wang, Burhan Jama, Jack D Bui, Gerald P Morris
15 May 2023